publication date: Feb. 28, 2017

Renal Cell Carcinoma NKTR-214 Shows Activity in Phase I RCC Study

Nektar Therapeutics presented positive phase I data for Nektar’s lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma.

The data were presented at ASCO GU 2017.

NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and Natural Killer cells.

“NKTR-214 resulted in dramatic increases in tumor-infiltrating lymphocytes and also demonstrated encouraging anti-tumor activity, with 40% of RCC patients experiencing tumor reductions, including one patient with a partial response,” said Mary Tagliaferri, vice president, clinical development, at Nektar. “We know that high TIL levels are correlated with clinical response and longer survival in patients treated with checkpoint inhibitor therapies and can be the best predictor of response. NKTR-214’s unique mechanism, favorable safety profile and clinical activity support our combination trials of NKTR-214 with existing checkpoint inhibitors, such as nivolumab and atezolizumab, but also with other I-O mechanisms in development.”

Clinical benefit and safety data were presented on 15 patients from the trial with renal cell carcinoma who were treated with single-agent NKTR-214:

6/15 (40%) patients with RCC had radiographic reductions in tumor size per RECIST 1.1 on NKTR-214, including: o 3 patients who had progressed on 1 prior tyrosine kinase inhibitor (TKI) and had also progressed on 1 prior checkpoint therapy o 3 patients who had progressed … Continue reading CCL Feb 2017 – NKTR-214 Shows Activity in Phase I RCC Study

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.